IO Biotech, Inc. IOBT 深 沪
等待开盘 09-30 09:30:00 美东时间
0.3651
-1.215
-76.89%
华盛通- 最 高0.48
- 今 开0.358
- 成交量 3671.66万股
- 最 低 0.3234
- 昨 收 1.58
- 总市值 2405.31万
- 52周最高 2.79
- 市盈率 静 --
- 换手率 55.73%
- 52周最低 0.3234
- 委 比 94.06%
- 总股本 6588.09万
- 历史最高 17.88
- 量 比 37.60
- 振 幅 9.91%
- 历史最低 0.3234
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IO Biotech Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
今天 00:23
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
IO Biotech announced FDA's recommendation against submitting a BLA for Cylembio based on IOB-013 trial data due to lack of statistical significance, despite improved progression-free survival. The company plans to redesign a registrational study for advanced melanoma treatment and will engage with EU regulators. To conserve capital, IO Biotech is restructuring, cutting its workforce by approximately 50%. The company expects to incur a one-time ch...
09-29 11:05
IO Biotech To Present Phase 3 And Final Phase 2 Trial Results For IO102-IO103 Cancer Vaccine Plus Pembrolizumab At 2025 ESMO Congress
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster presentation will share final
09-23 20:06
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
IO Biotech announced that late-breaking abstracts have been accepted for their cancer vaccine, IO102-IO103, in combination with pembrolizumab, at the 2025 ESMO Congress. The oral presentation will present Phase 3 trial results for first-line advanced melanoma, while the poster session will share Phase 2 basket trial data for solid tumors, including NSCLC and SCCHN. Jessica Hassel, MD, will present the melanoma data, and Jonathan W. Riess, MD, MS,...
09-23 12:05
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech's senior management will present at Morgan Stanley's Global Healthcare Conference on September 9 and H.C. Wainwright's Global Investment Conference on September 10. The company's lead candidate, Cylembio, is in pivotal Phase 3 and two Phase 2 trials for advanced melanoma and solid tumors, with results expected in Q3 2025. IO Biotech is a clinical-stage biopharma company developing immune-modulatory cancer vaccines.
09-04 12:05
美股牛股 | 中概股迅雷涨26.5%；生物制药公司IO Biotech涨68.8%
IO Biotech, Inc.涨68.8%；PRECIGEN涨58.9%；Sunrun涨32.8%
08-16 09:33
IO Biotech Q2 EPS $(0.40) Misses $(0.35) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 13.64 percent. This is a 29.03 percent decrease over losses of $(0.31) per share from the
08-15 04:35
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech reported Q2 2025 results, including a Phase 3 trial of Cylembio® + KEYTRUDA® showing clinical improvement in progression-free survival (PFS) vs. KEYTRUDA alone in advanced melanoma, though statistical significance was narrowly missed. The company plans to meet with FDA this fall to discuss data. Cash ended Q2 at $28.1M, with funds from European Investment Bank expected to support operations into 2026. IO Biotech will present at the Mor...
08-14 20:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
Market-Moving News for August 11th
MNDY: -19% | Monday.Com Q2 Adj. EPS $1.09 Beats $0.86 Estimate, Sales $299.01M Beat $293.54M Estimate IOBT: 66% | Reported Sunday, IO Biotech To Reveal Topline Phase 3 Results For Cylembio Plus KEYTRUDA In
08-11 19:25
